SEC Form 6-K filed by Qiagen N.V.
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
FORM 6-K
__________________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 30, 2024
Commission File Number 001-38332
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F o
1
QIAGEN N.V.
Form 6-K
Table of Contents
Other Information
On June 21, 2024, QIAGEN N.V (NYSE: QGEN; Frankfurt Prime Standard: QIA) held the Annual General Meeting of Shareholders. The related materials are furnished herewith as Exhibit 99.1 to 99.7 and are incorporated by reference herein.
3
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| QIAGEN N.V. | |||||
| By: | /s/ Roland Sackers | ||||
| Roland Sackers | |||||
| Chief Financial Officer | |||||
| Date: | August 1, 2024 | ||||
4
Exhibit Index
Exhibit No. | Exhibit | |||||||
| Notice 2024 AGM QIAGEN N.V. | ||||||||
| Proxy Statement 2024 | ||||||||
| Beneficial Shareholder Attendance Form 2024 | ||||||||
| Registered Shareholder Attendance Form 2024 | ||||||||
| Proxy Card for 2024 Annual General Meeting of Shareholders | ||||||||
| 2024 QIAGEN AGM Voting Results | ||||||||
| 2023 IFRS Annual Report | ||||||||
5